Journal article

Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic Lymphoma

Veronique Leblond, Steve Johnson, Sylvie Chevret, Adrian Copplestone, Simon Rule, Olivier Tournilhac, John Francis Seymour, Russell D Patmore, David Wright, Pierre Morel, Marie-Sarah Dilhuydy, Sara Willoughby, Caroline Dartigeas, Marion Malphettes, Bruno Royer, Maeve Ewings, Guy Pratt, Julie Lejeune, Florence Nguyen-Khac, Sylvain Choquet Show all

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2013


Funding Acknowledgements

Supported by Schering and Bayer Pharmaceuticals; Genzyme provided fludarabine for French patients; and Schering Health Care supported the United Kingdom Web site.Although all authors completed the disclosure declaration, the following author(s) and/or an author's immediate family member(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "U" are those for which no compensation was received; those relationships marked with a "C" were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors. Employment or Leadership Position: None Consultant or Advisory Role: Veronique Leblond, Roche (C); Russell D. Patmore, Roche (C); Sylvain Choquet, Roche (C) Stock Ownership: None Honoraria: Veronique Leblond, Janssen-Cilag, Mundipharma; Steve Johnson, Schering Health Care; Olivier Tournilhac, GlaxoSmithKline, Janssen-Cilag, Mundipharma, Roche; Roger G. Owen, Celgene, Ortho Biotech, Roche Research Funding: Veronique Leblond, Genzyme Expert Testimony: None Other Remuneration: None